Psoriatic Arthritis News

EULAR has initiated a survey that will collect data directly from patients on the impact and outcomes of rheumatic and musculoskeletal diseases, according to a statement released during the EULAR 2023 Congress.

EULAR has launched RheumaFacts, a novel resource for local and national data regarding rheumatic and musculoskeletal diseases in Europe, according to a presenter at the EULAR 2023 Congress.

Spatial transcriptomic profiling showed that lesional and distal, nonlesional areas in patients with psoriasis stratify by disease severity and not by the presence of disease, according to a study from NYU Langone Health.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

UCB announced new long-term data from BE COMPLETE’s 52-week open label extension evaluating the efficacy and safety of bimekizumab in adults with active psoriatic arthritis, according to a press release.

Joint pain and decreased daily physical activity can contribute to patients with psoriatic arthritis having trouble falling or staying asleep, but the sleep issues often are overlooked and go untreated, according to researchers.

The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.

Properly managing cardiovascular disease in patients with immune-mediated inflammatory diseases requires following guidelines and inter-specialty collaboration, according to a speaker at the Biologic Therapies Summit.

The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.

The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.